Back to PharmaIndex

Arbitel-MT 50 Tablet ER

Telmisartan (40mg) + Metoprolol Succinate (50mg)

Drug details

API

Telmisartan (40mg) + Metoprolol Succinate (50mg)

Drug classification

Antihypertensive; Angiotensin II receptor blocker (telmisartan) and beta-1 selective blocker (metoprolol).

Dosage form

Extended-release oral tablet containing telmisartan and metoprolol succinate.

API strength per dosage

Dose

Arbitel-MT 50 Tablet ER combines telmisartan 40 mg and metoprolol succinate 50 mg, typically taken once daily in adults. Dose adjustments may be needed in hepatic impairment (especially for telmisartan) and severe renal impairment. Safety and efficacy in children have not been established. Always individualize dosing based on clinical response and tolerability.

Mechanism of action

Telmisartan blocks angiotensin II type 1 (AT1) receptors, reducing vasoconstriction and aldosterone effects, lowering blood pressure. Metoprolol succinate selectively inhibits β1-adrenergic receptors, decreasing heart rate and myocardial contractility, also reducing blood pressure. Together, they provide additive antihypertensive effects via complementary mechanisms.

Indications

Treatment of Hypertension (high blood pressure)

Side effects

Headache Weakness Dizziness Cold extremities Slow heart rate Increased potassium level in blood Numbness of extremity Decreased blood pressure

Pregnancy category

Telmisartan is contraindicated in pregnancy due to fetal toxicity risk; metoprolol should be used only if clearly needed, after risk-benefit assessment.

Precautions

Monitor blood pressure, heart rate, renal function, electrolytes, signs of heart failure, hepatic function, risk of hyperkalemia, bradycardia, hypotension, avoid abrupt withdrawal, caution in asthma/COPD, diabetes, pregnancy, severe renal/hepatic impairment, drug interactions, monitor for dizziness or fatigue.

Contraindications

Hypersensitivity to telmisartan, metoprolol, or excipients, pregnancy, severe bradycardia, second- or third-degree heart block, cardiogenic shock, overt cardiac failure, severe hepatic impairment, severe hypotension, sick sinus syndrome (without pacemaker).

PharmaProLearn

Excel Beyond Limits